[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Acute Myeloid Leukemia (AML) Therapeutic Market Report 2016

November 2016 | 114 pages | ID: UABF2276D00EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Notes:

Sales, means the sales volume of Acute Myeloid Leukemia (AML) Therapeutic

Revenue, means the sales value of Acute Myeloid Leukemia (AML) Therapeutic

This report studies sales (consumption) of Acute Myeloid Leukemia (AML) Therapeutic in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
  • Ambit Biosciences Inc. (US)
  • Aprea AB (Sweden)
  • Astellas Pharma Inc. (Japan)
  • Astex Pharmaceuticals, Inc. (US)
  • Bio-Path Holdings, Inc. (US)
  • BioSante Pharmaceuticals, Inc. (US)
  • Celator Pharmaceuticals, Inc. (US)
  • Celgene Corp. (US)
  • Clavis Pharma ASA (Norway)
  • Cyclacel Pharmaceuticals, Inc. (US)
  • EpiCept Corp. (US)
  • Genzyme Corporation (US)
  • Lorus Therapeutics, Inc. (Canada)
  • Novartis AG (Switzerland)
  • Onconova Therapeutics, Inc. (US)
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
  • Type I
  • Type II
  • Type III
Split by applications, this report focuses on sales, market share and growth rate of Acute Myeloid Leukemia (AML) Therapeutic in each application, can be divided into
  • Application 1
  • Application 2
  • Application 3
United States Acute Myeloid Leukemia (AML) Therapeutic Market Report 2016

1 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC OVERVIEW

1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Therapeutic
1.2 Classification of Acute Myeloid Leukemia (AML) Therapeutic
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Acute Myeloid Leukemia (AML) Therapeutic
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Acute Myeloid Leukemia (AML) Therapeutic (2011-2021)
  1.4.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)
  1.4.2 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

2 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC COMPETITION BY MANUFACTURERS

2.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Acute Myeloid Leukemia (AML) Therapeutic Average Price by Manufactures (2015 and 2016)
2.4 Acute Myeloid Leukemia (AML) Therapeutic Market Competitive Situation and Trends
  2.4.1 Acute Myeloid Leukemia (AML) Therapeutic Market Concentration Rate
  2.4.2 Acute Myeloid Leukemia (AML) Therapeutic Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type (2011-2016)
3.2 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)
3.3 United States Acute Myeloid Leukemia (AML) Therapeutic Price by Type (2011-2016)
3.4 United States Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Type (2011-2016)

4 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application (2011-2016)
4.2 United States Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MANUFACTURERS PROFILES/ANALYSIS

5.1 Ambit Biosciences Inc. (US)
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Aprea AB (Sweden)
  5.2.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Astellas Pharma Inc. (Japan)
  5.3.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Astex Pharmaceuticals, Inc. (US)
  5.4.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 Bio-Path Holdings, Inc. (US)
  5.5.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 BioSante Pharmaceuticals, Inc. (US)
  5.6.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Celator Pharmaceuticals, Inc. (US)
  5.7.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Celgene Corp. (US)
  5.8.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Clavis Pharma ASA (Norway)
  5.9.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Cyclacel Pharmaceuticals, Inc. (US)
  5.10.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 EpiCept Corp. (US)
5.12 Genzyme Corporation (US)
5.13 Lorus Therapeutics, Inc. (Canada)
5.14 Novartis AG (Switzerland)
5.15 Onconova Therapeutics, Inc. (US)

6 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MANUFACTURING COST ANALYSIS

6.1 Acute Myeloid Leukemia (AML) Therapeutic Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MARKET FORECAST (2016-2021)

10.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue Forecast (2016-2021)
10.2 United States Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Type (2016-2021)
10.3 United States Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Application (2016-2021)
10.4 Acute Myeloid Leukemia (AML) Therapeutic Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Picture of Acute Myeloid Leukemia (AML) Therapeutic
Table Classification of Acute Myeloid Leukemia (AML) Therapeutic
Figure United States Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type in 2015
Table Application of Acute Myeloid Leukemia (AML) Therapeutic
Figure United States Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Application in 2015
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales of Key Manufacturers (2015 and 2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers
Figure 2016 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers
Table United States Acute Myeloid Leukemia (AML) Therapeutic Revenue by Manufacturers (2015 and 2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers
Table 2016 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers
Table United States Market Acute Myeloid Leukemia (AML) Therapeutic Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Acute Myeloid Leukemia (AML) Therapeutic Average Price of Key Manufacturers in 2015
Figure Acute Myeloid Leukemia (AML) Therapeutic Market Share of Top 3 Manufacturers
Figure Acute Myeloid Leukemia (AML) Therapeutic Market Share of Top 5 Manufacturers
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Type (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share by Type in 2015
Table United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Price by Type (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share by Application (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share by Application in 2015
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Application (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Application (2011-2016)
Table Ambit Biosciences Inc. (US) Basic Information List
Table Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Aprea AB (Sweden) Basic Information List
Table Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Astellas Pharma Inc. (Japan) Basic Information List
Table Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Astex Pharmaceuticals, Inc. (US) Basic Information List
Table Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Bio-Path Holdings, Inc. (US) Basic Information List
Table Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table BioSante Pharmaceuticals, Inc. (US) Basic Information List
Table BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Celator Pharmaceuticals, Inc. (US) Basic Information List
Table Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Celgene Corp. (US) Basic Information List
Table Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Clavis Pharma ASA (Norway) Basic Information List
Table Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Cyclacel Pharmaceuticals, Inc. (US) Basic Information List
Table Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table EpiCept Corp. (US) Basic Information List
Table EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Genzyme Corporation (US) Basic Information List
Table Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Lorus Therapeutics, Inc. (Canada) Basic Information List
Table Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Novartis AG (Switzerland) Basic Information List
Table Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Onconova Therapeutics, Inc. (US) Basic Information List
Table Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Table Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Acute Myeloid Leukemia (AML) Therapeutic
Figure Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic
Figure Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis
Table Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015
Table Major Buyers of Acute Myeloid Leukemia (AML) Therapeutic
Table Distributors/Traders List
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Production and Growth Rate Forecast (2016-2021)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Production Forecast by Type (2016-2021)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Consumption Forecast by Application (2016-2021)

More Publications

Need Help?

Ask a Question

Market Reports

All Categories